SPRY stock forecast, quote, news & analysis
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U... Show more
Why ARS Pharmaceuticals (SPRY) Stock Is Down -28.9% in the Last 30 Days
Key Takeaways
- SPRY shares fell roughly 28.9% over the last 30 days, declining from about $4.29 to approximately $3.05.
- The move extends a longer slide that has taken the stock from roughly $6.24 in early August 2026 to about $3.05 in early November.
- Pressure reflects concerns around the commercialization of neffy in a deeply entrenched epinephrine market, alongside a securities class action lawsuit overhang.
- Second-quarter 2026 revenue rose to $33.7 million, but the net loss widened to $62.3 million, keeping the path to profitability in focus.
- Management is cutting costs and targeting cash flow breakeven by the end of 2027, with about $143.8 million in cash and short-term investments as of June 30, 2026.
- For more detail on valuation and expectations, explore the company's Price Targets, Earnings, and Forecast pages.
- Investors tracking momentum and systematic strategies can also explore Trending AI Robots.
ARS Pharmaceuticals (SPRY) Company Overview and Market Position
ARS Pharmaceuticals is a biopharmaceutical company focused on protecting patients from severe allergic reactions that can lead to anaphylaxis. Its lead product, neffy (marketed as EURneffy in the European Union), is a needle-free epinephrine nasal spray approved for the emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and children. The company has secured approvals across multiple geographies, including the United States, the European Union, China, and Australia, and has been building a commercial organization to expand prescriber and patient adoption.
Investors follow SPRY closely because neffy represents a differentiated alternative to traditional epinephrine auto-injectors, which have long dominated the anaphylaxis market. The company's growth story centers on converting entrenched prescriber habits toward a needle-free option while expanding its global footprint and advancing a pipeline that includes an intranasal epinephrine program for chronic spontaneous urticaria.
ARS Pharmaceuticals (SPRY) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, SPRY has moved decisively lower. The shares closed near $4.29 in early October 2026 and slipped to roughly $3.05 by early November, a decline of approximately 28.9%. The move was not a single-day event but rather a steady erosion, with the stock trading below $4.00 through late October and testing the low-$3.00 range in the opening days of November.
The quarterly picture is even more pronounced. After closing near $6.24 in early August 2026, SPRY has declined to about $3.05, a drop of more than 50% over roughly three months. The shares sit well below their 52-week high and near the lower end of a broad trading range, reflecting a sustained shift in investor sentiment rather than a short-lived pullback.
What Drove SPRY Stock Price in the Last 30 Days
The recent decline has been driven less by a single headline and more by an accumulation of concerns tied to commercial execution and legal risk. The company is competing in an anaphylaxis market long dominated by entrenched epinephrine auto-injectors, and converting prescriber behavior has proven slower than some investors had hoped. Management has publicly acknowledged that inspiring change in this entrenched market requires provider-by-provider engagement, a process that takes time.
A securities class action lawsuit, with a class period spanning March 2026 through June 2026, has added a legal overhang that can weigh on sentiment in a commercial-stage biotech with no meaningful earnings support. Broader risk-off positioning across small- and mid-cap biotech names has also contributed, as investors have favored profitable, lower-risk companies during periods of market uncertainty. The combination of execution questions, litigation risk, and sector-wide caution has kept sustained buying pressure muted.
What Drove SPRY Stock Performance Over the Last Quarter
The quarterly decline reflects a reassessment of SPRY's valuation after an earlier period of optimism. The company has delivered growing neffy revenue, with second-quarter 2026 product revenue of $26.2 million contributing to total revenue of $33.7 million, but the net loss widened to $62.3 million as the company invested in its sales force and commercial infrastructure.
In response, management has refocused its strategy, shifting spending away from broad consumer advertising toward targeted engagement with high-volume prescribers, implementing cost reductions, and targeting cash flow breakeven by the end of 2027. These measures signal a more disciplined approach, but they also highlight the balance the company must strike between investing in neffy adoption and controlling losses. For a pre-profitability commercial-stage company, this tradeoff has kept the stock under pressure even as underlying revenue grows.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of algorithmic trading bots drawn from a much larger universe of strategies. Tickeron offers hundreds of AI-driven bots that collectively trade thousands of tickers, yet only the top-performing and most relevant bots are featured in this section. The bots vary widely in strategy, timeframe, and performance metrics, giving traders the ability to evaluate systematic approaches that match different risk profiles and market conditions. For investors looking to complement their research with data-driven signals, exploring the page can offer a practical view of how AI is applied to active trading.
SPRY Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors will shape SPRY's trajectory. Prescription growth and market-share gains for neffy remain the central metric, particularly as refill cycles mature and expanded payer access, including potential formulary additions, takes effect. Progress toward the company's cash flow breakeven target for the end of 2027 will be closely monitored, as will any updates on the securities litigation.
International commercialization, including regulatory milestones and launches in new markets, provides additional catalysts, while the Phase 2b trial for ARS-2 in chronic spontaneous urticaria offers a longer-term pipeline opportunity. Competitive dynamics in the epinephrine market, broader biotech sentiment, and the company's ability to control operating expenses will all influence how investors value the shares in the months ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for SPRY turns positive, indicating new upward trend
SPRY saw its Momentum Indicator move above the 0 level on November 11, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In 80 of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SPRY's RSI Oscillator exited the oversold zone, 28 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for SPRY just turned positive on November 11, 2026. Looking at past instances where SPRY's MACD turned positive, the stock continued to rise in 42 of 49 cases over the following month. The odds of a continued upward trend are 86%.
Following a +25.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRY advanced for three days, in 234 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SPRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for SPRY entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. SPRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.175) is normal, around the industry mean (3.498). P/E Ratio (-1.280) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.535) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology